A carregar...
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically treating underlying pathophysiological processes. DPP-4 inhib...
Na minha lista:
| Publicado no: | Eur Endocrinol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Touch Medical Media
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813466/ https://ncbi.nlm.nih.gov/pubmed/29632609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.62 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|